X
<

Novartis to Report 1Q17 Earnings Next Week: What to Expect

PART:
1 2 3 4 5 6
Part 6
Novartis to Report 1Q17 Earnings Next Week: What to Expect PART 6 OF 6

Analyst Ratings and Recommendations for Novartis

Wall Street analysts’ estimates

In 4Q16, Novartis (NVS) met Wall Street analysts’ estimates for EPS (earnings per share) at $1.12. However, the company missed analysts’ estimates for revenues in 4Q16 and reported revenues of ~$12.3 billion against estimated revenues of ~$12.4 billion.

Analyst Ratings and Recommendations for Novartis

Interested in GSK? Don't miss the next report.

Receive e-mail alerts for new research on GSK

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

For 1Q17, analysts estimate EPS of $1.12 with revenues of ~$11.7 billion compared to $11.6 billion in 1Q16.

Analysts’ ratings

Novartis stock has fallen nearly 3.9% over the last 12 months and has risen ~1.1% in 2017 year-to-date. The stock has a potential to rise ~15.8% over the next 12 months. Analyst recommendations show a 12-month target price of $85.25 per share compared to $73.62 on April 20, 2017.

Analyst recommendations

As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a “buy.” Two analysts have recommended a “hold.” Changes in analysts’ estimates and recommendations are based on the changing trends in a stock price and the performance of a company. The consensus rating for Novartis stands at 2.0, which represents a moderate “buy” for long-term growth investors.

To divest the risk, you can consider ETFs such as the PowerShares International Dividend Achievers ETF (PID), which holds 1.1% of its total assets in Novartis (NVS), 1.1% in Teva Pharmaceutical (TEVA), 2.4% in GlaxoSmithKline (GSK), and 1.5% in Sanofi (SNY).

X

Please select a profession that best describes you: